Investing.com -- Shares of Apellis Pharmaceuticals (NASDAQ: APLS) fell 8.9% in premarket trading following news that the FDA accepted a revised supplemental application from competitor Astellas Pharma ...

fell 8.9% in premarket trading following news that the FDA accepted a revised supplemental application from competitor Astellas Pharma for its eye drug, potentially leading to an earlier approval ...

The product may be used to treat a condition that the American Academy of Ophthalmology says affects around 20 million ...

Eylea (aflibercept) is a prescription drug that treats certain eye conditions. Eylea can cause side effects that range from mild to serious. An example includes cataracts, which may become a long ...

More than 3 million people in the U.S. are estimated to be living with glaucoma. By 2030, that number is expected to increase ...

Glaukos has invented by all accounts the world’s smallest medical device – smaller than the dot above this “j” that you are ...

Some megatrends in health care are occurring that deserve our attention. We already know that as much as one-third of the U.S ...

You may not have thought to invent these beauty products, but the next best thing you can do is buy them. View Entire Post › ...

Don’t believe everything you see We’ve all been there! After watching a clever hack online, you’ve likely thought to yourself ...

Editor’s Note: The Business Journal this week is honoring Gavin Herbert with our first ever Lifetime Achievement Recognition.

The top-line results come from BRIO-II, Tenpoint’s second phase 3 pivotal trial for Brimochol PF, a topical eye treatment the biotech plans to submit for FDA approval in the first half of this ...

FDA alerts and updates on the latest drug and device approvals, recalls, and other regulatory developments in ophthalmology.